We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Top Five IVD Sector Trends of 2015 Announced

By LabMedica International staff writers
Posted on 21 Dec 2015
Print article
Among the in vitro diagnostic (IVD) testing trends in 2015 were smaller molecular instruments, better information technology (IT) systems, and progress on use of sequencing in clinical medicine. These and additional findings were based on research covered in three new healthcare market reports.

Three main segments drive IVD sector. Kalorama Information (New York, NY, USA) describes 5 main trends based on their recently published 3 reports (see Related Links below), which delve into some of the fastest-growing and most critical areas of clinical diagnostics: cancer, infectious diseases, and molecular assays and systems. Together, these areas represent approximately 40% of the overall IVD market. The rate of growth for the combined segments is outpacing the growth of the overall IVD market by roughly 2 extra percentage points each year (+2% CAGR). Several subsegments of the cancer and molecular diagnostics markets are also growing at rates of over 8% each year.

Molecular Point-of-Care (POC) Becomes Reality: Alere announced its Alere i Influenza A & B that provides molecular flu results in less than 15 minutes. Cepheid launched its highly portable 9 inches tall GeneXpert Omni, enabling unprecedented access to accurate, fast diagnosis for patients suspected of having TB, HIV, and Ebola. Such products push infectious disease testing into the POC and near-patient testing arena, allowing providers to initiate treatment during the same visit or day.

Energetic Competitive Activity: The leader in IVD in 2015 remains the same as in 2014, but there was plenty of market activity, with scores of acquisitions, partnership deals, and distribution agreements. Roche Diagnostics remains the largest supplier of clinical diagnostics products; its product sales are still almost twice its nearest competitor. Roche stayed active in 2015, including a deal with Sigma-Aldrich, acquiring GeneWeave BioSciences, and becoming majority shareholder in cancer genomics company Foundation Medicine.

One competitor, automated nucleic acid extraction pioneer Qiagen, continued to grow, with close to 30% increase in IVD sales since 2010. Now Qiagen’s clinical business is moving from a base in infectious diseases to cancer testing and personalized medicine. It markets over 500 products in four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Liquid Biopsy: Numerous liquid biopsy tests and enterprises progressed in 2015. Genomic DNA amplified or sequenced from circulating tumor cells (CTCs), circulating tumor cell DNA (ctDNA), and circulating cell-free DNA (cfDNA) harbor complementary information on mutations relevant for the treatment of individual cancer patients. The technology has had its ups and downs but is still in contention. These applications will likely impact and determine the future standard of oncology care. cfDNA can be applied more broadly and will likely determine standard of care in oncology, transplant medicine, and cardiovascular disease. This emerging field has already made a huge impact on prenatal care. CTC technology is much more mature than that of cfDNA. Veridex (Janssen Diagnostics) has pioneered CTC testing.

Information Technology and Genomics: 2015 saw progress in use of IT for genomic medicine. Hundreds of genome studies are underway, involving sometimes hundreds of thousands of patient test results. Data-sharing, through private and public consortia, has become essential. The Global Alliance is a diverse international coalition of over 140 member organizations working together on open interfaces and catalytic projects to enable effective and responsible data-sharing and guide this quickly evolving field.

Related Links:
The World Market for Molecular Diagnostics, 6th Edition, report
The World Market for Cancer Diagnostics, 6th Edition, report
The World Market for Infectious Disease Diagnostic Tests, report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.